Fontana M G, Donato F, Villanacci V, Ghirardi M, Moneghini D, Di Betta E, Salerni B
Department of Surgery, University of Brescia, Brescia, Italy.
Eur Surg Res. 1999;31(5):406-11. doi: 10.1159/000008719.
This study tested the effect of a new gastrin receptor antagonist, CR2945, on colorectal cancer induced by 1,2-dimethylhydrazine (DMH) in mice. 75 CD1 male mice were divided into 3 groups: group 1 received 1 weekly injection of 20 mg/kg of DMH and 2 daily intraperitoneal injections of 0.5 ml of NaCl 0.9% solution for 5 weeks; groups 2 and 3 received the same weekly dose of DMH and 2 daily injections of CR2945 at the respective doses of 2.5 and 7.5 mg/kg for 5 weeks. The animals were sacrificed 25 and 38 weeks after the first injection. No tumours were found at the 25th week. A lower cancer frequency (4%) was observed in treated animals compared to controls (37.4%) at the 38th week (p = 0.002). These data show that CR2945 could prevent chemically induced colon cancer development in mice.
本研究测试了一种新型胃泌素受体拮抗剂CR2945对1,2 - 二甲基肼（DMH）诱导的小鼠结直肠癌的作用。75只CD1雄性小鼠被分为3组：第1组每周注射1次20 mg/kg的DMH，并每天腹腔注射2次0.5 ml 0.9%的氯化钠溶液，持续5周；第2组和第3组接受相同的每周DMH剂量，并分别每天注射2次剂量为2.5和7.5 mg/kg的CR2945，持续5周。在首次注射后25周和38周处死动物。在第25周未发现肿瘤。在第38周时，与对照组（37.4%）相比，治疗组动物的癌症发生率较低（4%）（p = 0.002）。这些数据表明，CR2945可以预防化学诱导的小鼠结肠癌的发生。
